Evaluation of the role of RANK and OPG genes in Paget's disease of bone

W Wuyts, L Van Wesenbeeck, A Morales-Piga, S Ralston, L Hocking, F Vanhoenacker, R Westhovens, L Verbruggen, D Anderson, A Hughes, W Van Hul

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Paget's disease of bone (PDB) is one of the most common bone disorders in the western world. PDB is characterized by focal areas of increased osteoclastic bone resorption and bone formation, which leads to the formation of poorly structured bone. These abnormalities of bone turnover and structure predispose affected individuals to various complications including bone pain, deformity, pathological fracture, and an increased risk of osteosarcoma. One of the main mechanisms of osteoclast formation and activation involves the receptor activator of nuclear factor -kappaB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) pathway, where binding of RANKL to RANK results in the differentiation of osteoclast precursors. OPG, on the other hand, acts as an inhibitor of osteoclastogenesis by serving as a decoy receptor for RANKL. Recently, mutations in the RANK gene have been shown to cause familial expansile osteolysis, a rare bone disorder showing great similarity to PDB. We performed mutation analysis in the RANK and OPG genes in 28 PDB patients to investigate whether mutations in these genes could be responsible for PDB. Our data suggest that RANK is not directly involved in PDB in our set of patients, as no mutations in the RANK coding region could be identified and allele frequencies of RANK polymorphisms did not differ in PDB patients as compared with the random population. Also, in the OPG gene, we could not detect PDB-causing mutations. However, of the several polymorphisms identified, one (400 + 4 C/T in intron 2), showed a statistically significant increased frequency for the C allele in PDB patients, suggesting that individuals harboring this allele may be more susceptible for developing PDB.
Original languageEnglish
Pages (from-to)104-107
Number of pages4
JournalBone
Volume28
Issue number1
DOIs
Publication statusPublished - Jan 2001

Fingerprint

Receptor Activator of Nuclear Factor-kappa B
Osteitis Deformans
Osteoprotegerin
Genes
RANK Ligand
Bone and Bones
Mutation
Osteoclasts
Gene Frequency
Osteogenesis
Spontaneous Fractures
Western World
Bone Remodeling
Osteosarcoma
Bone Resorption
Introns

Keywords

  • carrier proteins
  • DNA mutational analysis
  • DNA primers
  • family health
  • glycoproteins
  • humans
  • membrane glycoproteins
  • molecular sequence data
  • osteitis deformans
  • osteoprotegerin
  • polymorphism, single nucleotide
  • polymorphism, single-stranded conformational
  • RANK ligand
  • receptor activator of nuclear factor-kappa B
  • receptors, cytoplasmic and nuclear
  • receptors, tumor necrosis factor

Cite this

Wuyts, W., Van Wesenbeeck, L., Morales-Piga, A., Ralston, S., Hocking, L., Vanhoenacker, F., ... Van Hul, W. (2001). Evaluation of the role of RANK and OPG genes in Paget's disease of bone. Bone, 28(1), 104-107. https://doi.org/10.1016/S8756-3282(00)00411-7

Evaluation of the role of RANK and OPG genes in Paget's disease of bone. / Wuyts, W; Van Wesenbeeck, L; Morales-Piga, A; Ralston, S; Hocking, L; Vanhoenacker, F; Westhovens, R; Verbruggen, L; Anderson, D; Hughes, A; Van Hul, W.

In: Bone, Vol. 28, No. 1, 01.2001, p. 104-107.

Research output: Contribution to journalArticle

Wuyts, W, Van Wesenbeeck, L, Morales-Piga, A, Ralston, S, Hocking, L, Vanhoenacker, F, Westhovens, R, Verbruggen, L, Anderson, D, Hughes, A & Van Hul, W 2001, 'Evaluation of the role of RANK and OPG genes in Paget's disease of bone' Bone, vol. 28, no. 1, pp. 104-107. https://doi.org/10.1016/S8756-3282(00)00411-7
Wuyts W, Van Wesenbeeck L, Morales-Piga A, Ralston S, Hocking L, Vanhoenacker F et al. Evaluation of the role of RANK and OPG genes in Paget's disease of bone. Bone. 2001 Jan;28(1):104-107. https://doi.org/10.1016/S8756-3282(00)00411-7
Wuyts, W ; Van Wesenbeeck, L ; Morales-Piga, A ; Ralston, S ; Hocking, L ; Vanhoenacker, F ; Westhovens, R ; Verbruggen, L ; Anderson, D ; Hughes, A ; Van Hul, W. / Evaluation of the role of RANK and OPG genes in Paget's disease of bone. In: Bone. 2001 ; Vol. 28, No. 1. pp. 104-107.
@article{56958192d27a4e77a2bf8126abe626cd,
title = "Evaluation of the role of RANK and OPG genes in Paget's disease of bone",
abstract = "Paget's disease of bone (PDB) is one of the most common bone disorders in the western world. PDB is characterized by focal areas of increased osteoclastic bone resorption and bone formation, which leads to the formation of poorly structured bone. These abnormalities of bone turnover and structure predispose affected individuals to various complications including bone pain, deformity, pathological fracture, and an increased risk of osteosarcoma. One of the main mechanisms of osteoclast formation and activation involves the receptor activator of nuclear factor -kappaB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) pathway, where binding of RANKL to RANK results in the differentiation of osteoclast precursors. OPG, on the other hand, acts as an inhibitor of osteoclastogenesis by serving as a decoy receptor for RANKL. Recently, mutations in the RANK gene have been shown to cause familial expansile osteolysis, a rare bone disorder showing great similarity to PDB. We performed mutation analysis in the RANK and OPG genes in 28 PDB patients to investigate whether mutations in these genes could be responsible for PDB. Our data suggest that RANK is not directly involved in PDB in our set of patients, as no mutations in the RANK coding region could be identified and allele frequencies of RANK polymorphisms did not differ in PDB patients as compared with the random population. Also, in the OPG gene, we could not detect PDB-causing mutations. However, of the several polymorphisms identified, one (400 + 4 C/T in intron 2), showed a statistically significant increased frequency for the C allele in PDB patients, suggesting that individuals harboring this allele may be more susceptible for developing PDB.",
keywords = "carrier proteins, DNA mutational analysis, DNA primers, family health, glycoproteins, humans, membrane glycoproteins, molecular sequence data, osteitis deformans, osteoprotegerin, polymorphism, single nucleotide, polymorphism, single-stranded conformational, RANK ligand, receptor activator of nuclear factor-kappa B, receptors, cytoplasmic and nuclear, receptors, tumor necrosis factor",
author = "W Wuyts and {Van Wesenbeeck}, L and A Morales-Piga and S Ralston and L Hocking and F Vanhoenacker and R Westhovens and L Verbruggen and D Anderson and A Hughes and {Van Hul}, W",
year = "2001",
month = "1",
doi = "10.1016/S8756-3282(00)00411-7",
language = "English",
volume = "28",
pages = "104--107",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Evaluation of the role of RANK and OPG genes in Paget's disease of bone

AU - Wuyts, W

AU - Van Wesenbeeck, L

AU - Morales-Piga, A

AU - Ralston, S

AU - Hocking, L

AU - Vanhoenacker, F

AU - Westhovens, R

AU - Verbruggen, L

AU - Anderson, D

AU - Hughes, A

AU - Van Hul, W

PY - 2001/1

Y1 - 2001/1

N2 - Paget's disease of bone (PDB) is one of the most common bone disorders in the western world. PDB is characterized by focal areas of increased osteoclastic bone resorption and bone formation, which leads to the formation of poorly structured bone. These abnormalities of bone turnover and structure predispose affected individuals to various complications including bone pain, deformity, pathological fracture, and an increased risk of osteosarcoma. One of the main mechanisms of osteoclast formation and activation involves the receptor activator of nuclear factor -kappaB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) pathway, where binding of RANKL to RANK results in the differentiation of osteoclast precursors. OPG, on the other hand, acts as an inhibitor of osteoclastogenesis by serving as a decoy receptor for RANKL. Recently, mutations in the RANK gene have been shown to cause familial expansile osteolysis, a rare bone disorder showing great similarity to PDB. We performed mutation analysis in the RANK and OPG genes in 28 PDB patients to investigate whether mutations in these genes could be responsible for PDB. Our data suggest that RANK is not directly involved in PDB in our set of patients, as no mutations in the RANK coding region could be identified and allele frequencies of RANK polymorphisms did not differ in PDB patients as compared with the random population. Also, in the OPG gene, we could not detect PDB-causing mutations. However, of the several polymorphisms identified, one (400 + 4 C/T in intron 2), showed a statistically significant increased frequency for the C allele in PDB patients, suggesting that individuals harboring this allele may be more susceptible for developing PDB.

AB - Paget's disease of bone (PDB) is one of the most common bone disorders in the western world. PDB is characterized by focal areas of increased osteoclastic bone resorption and bone formation, which leads to the formation of poorly structured bone. These abnormalities of bone turnover and structure predispose affected individuals to various complications including bone pain, deformity, pathological fracture, and an increased risk of osteosarcoma. One of the main mechanisms of osteoclast formation and activation involves the receptor activator of nuclear factor -kappaB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) pathway, where binding of RANKL to RANK results in the differentiation of osteoclast precursors. OPG, on the other hand, acts as an inhibitor of osteoclastogenesis by serving as a decoy receptor for RANKL. Recently, mutations in the RANK gene have been shown to cause familial expansile osteolysis, a rare bone disorder showing great similarity to PDB. We performed mutation analysis in the RANK and OPG genes in 28 PDB patients to investigate whether mutations in these genes could be responsible for PDB. Our data suggest that RANK is not directly involved in PDB in our set of patients, as no mutations in the RANK coding region could be identified and allele frequencies of RANK polymorphisms did not differ in PDB patients as compared with the random population. Also, in the OPG gene, we could not detect PDB-causing mutations. However, of the several polymorphisms identified, one (400 + 4 C/T in intron 2), showed a statistically significant increased frequency for the C allele in PDB patients, suggesting that individuals harboring this allele may be more susceptible for developing PDB.

KW - carrier proteins

KW - DNA mutational analysis

KW - DNA primers

KW - family health

KW - glycoproteins

KW - humans

KW - membrane glycoproteins

KW - molecular sequence data

KW - osteitis deformans

KW - osteoprotegerin

KW - polymorphism, single nucleotide

KW - polymorphism, single-stranded conformational

KW - RANK ligand

KW - receptor activator of nuclear factor-kappa B

KW - receptors, cytoplasmic and nuclear

KW - receptors, tumor necrosis factor

U2 - 10.1016/S8756-3282(00)00411-7

DO - 10.1016/S8756-3282(00)00411-7

M3 - Article

VL - 28

SP - 104

EP - 107

JO - Bone

JF - Bone

SN - 8756-3282

IS - 1

ER -